Is phosphorylation site disruption associated with cancer? Maricel G. Kann (University of Maryland,...
-
Upload
merilyn-armstrong -
Category
Documents
-
view
212 -
download
0
Transcript of Is phosphorylation site disruption associated with cancer? Maricel G. Kann (University of Maryland,...
Is phosphorylation site disruption associated with cancer?
• Maricel G. Kann (University of Maryland, Baltimore County)
• Matthew E. Mort (Indiana University School of Medicine)
• Matthew Hahn (Indiana University)
1/6
• Pedreg Radivojac (Indiana University)
– NSF award DBI-0644017
• Sean D. Mooney (Indiana University School of Medicine)
– K22LM009135– R01LM009722– Grant from IU Biomedical Research
Council, Indiana University, the Showalter Trust and the Indiana Genomics Initiative.
Peter H. Baenziger – [email protected]
Peter H. Baenziger – [email protected] for Computational Biology and Bioinformatics
Indiana University School of Medicine
Phosphorylation
2/6
• Serine, Threonine, and Tyrosine are phosphorylatable.– Kinases phosphorylate.– Phosphatases dephosphorylate.
• Phosphorylation affects signaling pathways.• Kinase inhibitors such as Gleevec® (imatinib
mesylate) are important cancer treatment targets.
Peter H. Baenziger – [email protected]
Phosphorylation
3/6Peter H. Baenziger – [email protected]
• S, T, or Y specifically targeted by kinases.
• DisPhos predicts phosphorylation on sites.
• Hypothesis: mutations may disrupt kinase and phosphatase target sites.
Do mutations of target amino acids disrupt phosphorylation sites?
4/6Peter H. Baenziger – [email protected]
Somatic mutations from breast and colorectal cancer tumors
Somatic mutations from kinase genes of tumors from many
cancers
* *
*Random mutations
5/6Peter H. Baenziger – [email protected]
Do mutations of target amino acids disrupt phosphorylation sites?
Somatic mutations from breast and colorectal cancer tumors
Somatic mutations from kinase genes of tumors from many
cancers
Conclusions
6/6Peter H. Baenziger – [email protected]
• Phosphorylation site disruption might be a mechanism in cancer.
• Phosphorylation site disruption may be a useful feature in mutation classification.
• See poster for more information.